Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 15/20 | 0.48 |
| ▸ | PARP1 | P09874 | 5/20 | 0.45 |
| ▸ | KIT | P10721 | 2/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18780742 | 0.89 | KDR (0.52) | KDRKITPDGFRA | |
| SCHEMBL18780745 | 0.84 | KDR (0.43) | SCN9AKCNH2SCN5AKDRPARP1 | |
| SCHEMBL4812355 | 0.82 | KDR (0.64) | KDRPARP1 | |
| SCHEMBL13980537 | 0.81 | KDR (0.72) | KDR | |
| SCHEMBL18780748 | 0.80 | KDR (0.52) | KDRKITPDGFRA | |
| SCHEMBL23788989 | 0.79 | SCN9A (0.52) | SCN9AKCNH2SCN5AKIT | |
| SCHEMBL17260967 | 0.78 | KDR (0.55) | SCN9AKCNH2SCN5AKDRPARP1 | |
| SCHEMBL13980540 | 0.76 | KDR (0.54) | KDR | |
| SCHEMBL17979902 | 0.76 | PARP1 (0.51) | KDRPARP1KITPDGFRA | |
| SCHEMBL17261067 | 0.75 | KDR (0.50) | KDRPARP1KITPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114025-A1 | METHODS FOR INHIBITING NECROPTOSIS | CATALYST THERAPEUTICS PTY LTD (AU) | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114025-A1 | METHODS FOR INHIBITING NECROPTOSIS | RIPK1, RIPK3, RIPK2 | SCN9A 3657/4885KCNH2 2645/4885SCN5A 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.